<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859494</url>
  </required_header>
  <id_info>
    <org_study_id>CTD-2012-009-01</org_study_id>
    <nct_id>NCT01859494</nct_id>
  </id_info>
  <brief_title>Evaluation of an Investigational Blood Glucose Monitoring System</brief_title>
  <official_title>Performance of the Ninja 3 Blood Glucose Monitoring System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascensia Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascensia Diabetes Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine if untrained subjects who have diabetes can
      operate the Investigational Blood Glucose Monitoring System (BGMS) and obtain valid glucose
      results.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL (&lt;75mg/dL) or Within +/-20% (&gt;=75mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI Analyzer BG results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Self-Test Fingerstick Blood Glucose (BG)Results Within +/- 15mg/dL (&lt;100mg/L YSI) or Within +/- 15% (&gt;=100mg/dL YSI) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI BG results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 15% (&gt;=100mg/dL YSI capillary plasma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Self-Test Fingerstick Blood Glucose (BG)Results Within +/- 12.5mg/dL (&lt;100mg/L YSI) or Within +/- 12.5% (&gt;=100mg/dL YSI) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI BG results were used to calculate the number of BGMS results within +/- 12.5mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 12.5% (&gt;=100mg/dL YSI capillary plasma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/L YSI) or Within +/- 20% (&gt;=75mg/dL YSI) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <description>Untrained subjects with diabetes self-tested Alternative Site (AST) palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma BG results were used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject Fingerstick BG Results Within +/- 15mg/dL (&lt;75mg/L YSI) or Within +/- 20% (&gt;=75mg/dL YSI) of Laboratory Glucose Method When Tested by Study Staff</measure>
    <time_frame>1 hour</time_frame>
    <description>Study staff tested subject fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements</measure>
    <time_frame>1 hour</time_frame>
    <description>Staff obtained subject responses using short questionnaires to provide feedback on instructions for use and the basic operation of the BGMS. Subjects could respond 'Strongly Agree' 'Agree' 'Neutral' 'Disagree' or 'Strongly Disagree'.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Users of the Monitoring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NINJA 3 Investigational Blood Glucose Monitoring System</intervention_name>
    <description>Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
    <arm_group_label>Users of the Monitoring System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females, 18 years of age and older

          2. People with type 1 or type 2 diabetes

          3. Able to speak, read, and understand English

          4. Willing to complete all study procedures

        Exclusion Criteria:

          1. Hemophilia or any other bleeding disorder

          2. Pregnancy

          3. Physical, visual, or neurological impairments that would make the person unable to
             perform testing with the BGM

          4. Previously participated in a BG monitor study using the Ninja 3 BGMS

          5. Working for a medical laboratory, hospital, or other clinical setting that involves
             training on and clinical use of blood glucose monitors

          6. Working for a competitive medical device company, or having an immediate family member
             who works for such a company

          7. A condition which, in the opinion of the investigator or designee, would put the
             person or study conduct at risk.

        The enrollment criteria for the study population:

          1. At least 60% of subjects will be younger than age 65

          2. At least 20% of subjects will have type 1 diabetes

          3. At least 50% of subjects with type 2 diabetes wil be insulin users.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Bailey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMCR Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie J Klaff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainier Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2013</study_first_submitted>
  <study_first_submitted_qc>May 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <results_first_submitted>September 9, 2016</results_first_submitted>
  <results_first_submitted_qc>September 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2016</results_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>When it is cleared, results data will be provided.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two subjects were screen failures due to not meeting enrollment criteria. 221 consented but only 219 enrolled into study.</population>
      <group_list>
        <group group_id="B1">
          <title>Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" lower_limit="18" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Subjects provided more than one choice for Race, therefore the apparent frequency total for Race was different from the number of subjects.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL (&lt;75mg/dL) or Within +/-20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI Analyzer BG results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma).</description>
        <time_frame>1 hour</time_frame>
        <population>218 (219-1) Blood glucose results were analyzed. One subject discontinued from testing after low Blood Glucose (BG) fingerstick result (hypoglycemia AE), thus no reference result available for that subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL (&lt;75mg/dL) or Within +/-20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
          <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI Analyzer BG results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma).</description>
          <population>218 (219-1) Blood glucose results were analyzed. One subject discontinued from testing after low Blood Glucose (BG) fingerstick result (hypoglycemia AE), thus no reference result available for that subject.</population>
          <units>Blood Glucose results within 15mg/dL/20%</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Self-Test Fingerstick Blood Glucose (BG)Results Within +/- 15mg/dL (&lt;100mg/L YSI) or Within +/- 15% (&gt;=100mg/dL YSI) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI BG results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 15% (&gt;=100mg/dL YSI capillary plasma)</description>
        <time_frame>1 hour</time_frame>
        <population>218 (219-1) Blood glucose results were analyzed. One subject discontinued from testing after low BG fingerstick result (hypoglycemia AE), thus no reference result available for that subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Self-Test Fingerstick Blood Glucose (BG)Results Within +/- 15mg/dL (&lt;100mg/L YSI) or Within +/- 15% (&gt;=100mg/dL YSI) of Laboratory Glucose Method</title>
          <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI BG results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 15% (&gt;=100mg/dL YSI capillary plasma)</description>
          <population>218 (219-1) Blood glucose results were analyzed. One subject discontinued from testing after low BG fingerstick result (hypoglycemia AE), thus no reference result available for that subject.</population>
          <units>Blood Glucose results within 15mg/dL/15%</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Self-Test Fingerstick Blood Glucose (BG)Results Within +/- 12.5mg/dL (&lt;100mg/L YSI) or Within +/- 12.5% (&gt;=100mg/dL YSI) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI BG results were used to calculate the number of BGMS results within +/- 12.5mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 12.5% (&gt;=100mg/dL YSI capillary plasma)</description>
        <time_frame>1 hour</time_frame>
        <population>218 (219-1) Blood glucose results were analyzed. One subject discontinued from testing after low BG fingerstick result (hypoglycemia AE), thus no reference result available for that subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Self-Test Fingerstick Blood Glucose (BG)Results Within +/- 12.5mg/dL (&lt;100mg/L YSI) or Within +/- 12.5% (&gt;=100mg/dL YSI) of Laboratory Glucose Method</title>
          <description>Untrained subjects with diabetes self-tested fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI BG results were used to calculate the number of BGMS results within +/- 12.5mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 12.5% (&gt;=100mg/dL YSI capillary plasma)</description>
          <population>218 (219-1) Blood glucose results were analyzed. One subject discontinued from testing after low BG fingerstick result (hypoglycemia AE), thus no reference result available for that subject.</population>
          <units>Bld Glucose results w/in 12.5mg/dL/12.5%</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/L YSI) or Within +/- 20% (&gt;=75mg/dL YSI) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-tested Alternative Site (AST) palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma BG results were used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma)</description>
        <time_frame>1 hour</time_frame>
        <population>211 (219-8) Blood glucose results were analyzed. One subject discontinued from all testing after hypoglycemia Adverse Event. Three subjects with low blood sugar did not attempt palm testing per protocol. Two subjects had low blood sugar; their palm results were not evaluable per protocol. Two subjects failed to obtain palm blood for testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/L YSI) or Within +/- 20% (&gt;=75mg/dL YSI) of Laboratory Glucose Method</title>
          <description>Untrained subjects with diabetes self-tested Alternative Site (AST) palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results were compared with subject capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma BG results were used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma)</description>
          <population>211 (219-8) Blood glucose results were analyzed. One subject discontinued from all testing after hypoglycemia Adverse Event. Three subjects with low blood sugar did not attempt palm testing per protocol. Two subjects had low blood sugar; their palm results were not evaluable per protocol. Two subjects failed to obtain palm blood for testing.</population>
          <units>Blood Glucose results within 15mg/dL/20%</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject Fingerstick BG Results Within +/- 15mg/dL (&lt;75mg/L YSI) or Within +/- 20% (&gt;=75mg/dL YSI) of Laboratory Glucose Method When Tested by Study Staff</title>
        <description>Study staff tested subject fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma)</description>
        <time_frame>1 hour</time_frame>
        <population>218 (219-1) Blood glucose results were analyzed. One subject discontinued from testing after low BG result (hypoglycemia AE), thus no reference result available for that subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject Fingerstick BG Results Within +/- 15mg/dL (&lt;75mg/L YSI) or Within +/- 20% (&gt;=75mg/dL YSI) of Laboratory Glucose Method When Tested by Study Staff</title>
          <description>Study staff tested subject fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results were compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma results were used to calculate the number of BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma)</description>
          <population>218 (219-1) Blood glucose results were analyzed. One subject discontinued from testing after low BG result (hypoglycemia AE), thus no reference result available for that subject.</population>
          <units>Blood Glucose results within 15mg/dL/20%</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements</title>
        <description>Staff obtained subject responses using short questionnaires to provide feedback on instructions for use and the basic operation of the BGMS. Subjects could respond 'Strongly Agree' 'Agree' 'Neutral' 'Disagree' or 'Strongly Disagree'.</description>
        <time_frame>1 hour</time_frame>
        <population>218 (219-1) responses were analyzed. One subject discontinued from testing after low BG result (hypoglycemia Adverse Event).</population>
        <group_list>
          <group group_id="O1">
            <title>Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject Responses That 'Strongly Agree' or 'Agree' or Are 'Neutral' With Questionnaire Statements</title>
          <description>Staff obtained subject responses using short questionnaires to provide feedback on instructions for use and the basic operation of the BGMS. Subjects could respond 'Strongly Agree' 'Agree' 'Neutral' 'Disagree' or 'Strongly Disagree'.</description>
          <population>218 (219-1) responses were analyzed. One subject discontinued from testing after low BG result (hypoglycemia Adverse Event).</population>
          <units>Participant Responses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I find it easy to do a blood test with this meter.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The meter display was easy to see and read.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>It was easy to understand my test results.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I like the overall meter design.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I find the meter easy to use.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The instructions were easy to understand.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instructions clearly explain how to run a test.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instructions clearly explain meter error messages.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subject visits were approximately 1 hour.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
NINJA 3 Investigational Blood Glucose Monitoring System: Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Subjects' hypoglycemia events were resolved at the visit.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jane Wallace, Deputy Director for Global Clinical Affairs</name_or_title>
      <organization>Ascensia Diabetes Care</organization>
      <phone>574-257-3063</phone>
      <email>jane.wallace@ascensia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

